C
Catherine Dubos Arvis
Publications - 10
Citations - 4962
Catherine Dubos Arvis is an academic researcher. The author has contributed to research in topics: Pembrolizumab & Docetaxel. The author has an hindex of 8, co-authored 10 publications receiving 3894 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Journal ArticleDOI
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.
Roy S. Herbst,Edward B. Garon,Dong Wan Kim,Byoung Chul Cho,Jose Luis Perez-Gracia,Ji Youn Han,Catherine Dubos Arvis,Margarita Majem,Martin Forster,Isabelle Monnet,Silvia Novello,Zsuzsanna Szalai,Matthew A. Gubens,Wu Chou Su,Giovanni Luca Ceresoli,A. Samkari,Erin Jensen,Gregory M. Lubiniecki,Paul Baas +18 more
TL;DR: Pembrolizumab provided long-term OS benefit over docetaxel, with manageable safety, durable responses among patients receiving 2 years of treatment, and disease control with second-course treatment, further supporting pembrolIZumab for previously treated, PD-L1‒expressing advanced NSCLC.
Journal ArticleDOI
OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab
Roy S. Herbst,Edward B. Garon,Dong Wan Kim,Byoung Chul Cho,Shirish M. Gadgeel,Hervé Lena,Alfonso Gurpide,Ji-Youn Han,Catherine Dubos Arvis,Margarita Majem,Martin Forster,Isabelle Monnet,Silvia Novello,Hideo Saka,Zsuzsanna Szalai,Matthew A. Gubens,Wu Chou Su,Gregory M. Lubiniecki,Yue Shentu,Geri L Ferraro,Paul Baas +20 more
Journal ArticleDOI
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.
Paul Baas,Edward B. Garon,Roy S. Herbst,Enriqueta Felip,Jose Luis Perez-Gracia,Ji-Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Fabrice Barlesi,Gilberto de Castro,Marcelo Garrido,Yue Shentu,Gregory M. Lubiniecki,Ellie Im,Dong Wan Kim +18 more
TL;DR: Pembrolizumab (pembro; MK-3475) provided superior OS over docetaxel (doce) in patients (pts) with previously treated, PD-L1-positiv.
Journal ArticleDOI
Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji-Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Misoo C. Ellison,A. Samkari,Gregory M. Lubiniecki,Edward B. Garon +17 more
TL;DR: Factors associated with better OS for previously treated, PD-L1–expressing advanced NSCLC patients using data from KEYNOTE-010 are identified.